Phase 3 CLEAR Trial: Evaluating Organ-Specific Progression Patterns
Panelists discuss how the Phase phase 3 CLEAR trial evaluates organ-specific progression patterns in advanced renal cell carcinoma to better understand the efficacy of lenvatinib plus pembrolizumab compared to with sunitinib and guide subsequent treatment strategies.
Video Player is loading.
EP: 1.1L Treatment Landscape for Advanced Renal Cell Carcinoma
EP: 2.Metastatic Site–Specific Outcomes With 1L ccRCC Therapies
EP: 3.Clinical Decision-making With TKI-IO Combinations for Advanced RCC
Now Viewing
EP: 4.Phase 3 CLEAR Trial: Evaluating Organ-Specific Progression Patterns
EP: 5.Time to Progression by Organ with Lenvatinib Plus + Pembrolizumab in Advanced RCC.
EP: 6.CLEAR Follow-Uup Analysis: Implications for Clinical Decision MakingDecision-Making
EP: 7.Future Directions in Advanced RCC
Recent Videos
Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
Current Treatment Approaches in HER2+ Metastatic Breast Cancer
Making the Most of ADCs: Balancing Benefits and Managing Concerns in Ovarian Cancer
Advances in ADC Therapy for Ovarian Cancer
ASCO 2025: MonumenTAL-1 Extended Follow-Up for Talquetamab in R/R MM
Looking Ahead: What’s on the Horizon in Advanced Melanoma
CEPHEUS Trial: Design/Baseline Characteristics
Introduction/Treatment Overview of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Later R/R MM Treatment Landscape and Unmet Needs
Sequencing Melanoma Treatments: Strategies for Optimizing Patient Outcomes
Related Content
